Clinical trials: Prostatic Adenocarcinoma
Adenocarcinoma of the Prostate
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
This single arm, multicenter, open-label, Phase II study will enroll chemotherapy-naive participants with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2).
- Trial name
- NCT00520481
- Testing
- IMC-A12 (Cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Prostate Adenocarcinoma
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Cabozantinib (XL184) is a new drug that is being developed to treat cancer. Cabozantinib works by blocking the "angiogenesis," or the growth of new blood vessels, to the tumor.
- Trial name
- NCT01347788
- Testing
- cabozantinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, etoposide, and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00627354
- Testing
- etoposide, mitoxantrone hydrochloride, prednisone
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Groupe D'Etude des Tumeurs Uro-Genitales
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have…
- Trial name
- TALENT (NCT06844383)
- Testing
- Talazoparib with enzalutamide, Talazoparib
- Where
- 8 sites in United States
- Volunteers
- 126 people
- Sponsor
- Prostate Cancer Clinical Trials Consortium
Bone Metastases, Prostate Cancer
Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief
Radiation therapy has been shown to be very effective at relieving pain caused by bone metastases. However, certain types of cancers such as prostate, breast, kidney, and melanoma can have resistance to radiation, making…
- Conditions
- Bone Metastases, Prostate Cancer, Breast Cancer, Renal Cell Carcinoma
- Trial name
- SOLAR-P (NCT04177056)
- Testing
- SBRT
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00025194
- Testing
- estramustine phosphate sodium, ixabepilone
- Where
- 4 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
This randomized phase II trial will evaluate if a low omega-6, high omega-3 fat diet combined with fish oil has the potential to delay disease progression in patients with prostate cancer undergoing active surveillance.
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02176902
- Testing
- behavioral dietary intervention, omega-3 fatty acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Advanced Prostate Adenocarcinoma
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
- Trial name
- VERU-100 (NCT04843319)
- Testing
- VERU-100
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veru Inc.
Prostate Cancer, Prostate Cancer (Diagnosis)
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy
- Trial name
- CLIQQC (NCT07484971)
- Where
- 24 sites in Algeria
- Volunteers
- 2,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Prostate Adenocarcinoma
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet.
- Trial name
- NCT05832086
- Testing
- Fasting Mimicking Diet (FMD), Standard Anti-Cancer Diet
- Where
- 3 sites in United States
- Volunteers
- 138 people
- Sponsor
- Stephen Freedland
Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received…
- Conditions
- Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
- Trial name
- DeLLight (NCT06893783)
- Testing
- Tarlatamab
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Inkeun Park
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate…
- Trial name
- PROMPT (NCT04610372)
- Testing
- Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant
- Where
- 4 sites in Canada
- Volunteers
- 168 people
- Sponsor
- British Columbia Cancer Agency
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
Active Surveillance for Low Risk Prostate Cancer
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic…
- Trial name
- NCT04146077
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic).
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT01503229
- Testing
- Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Prostate Cancer
Study of Treatment Choice in Patients With Localized Prostate Cancer
RATIONALE: Gathering information about patients with prostate cancer may help doctors learn more about how patients choose treatment options.
- Trial name
- NCT01177865
- Testing
- informational intervention, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 432 people
- Sponsor
- University College London Hospitals
Prostate Cancer, Prostate Adenocarcinoma
Efficacy and Safety Assessment of IRE of Localized Prostate Cancer.
The purpose of this study is to evaluate safety and short-term oncological efficacy of the NanoKnife Irreversible Electroporation System for localised prostate cancer.
- Trial name
- NCT03504995
- Testing
- Focal irreversible electroporation of the prostate cancer
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.